Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design

por Levin, Bruce, Thompson, John LP, Chakraborty, Bibhas, Levy, Gilberto, MacArthur, Robert, Haley, E Clarke
Publicado 2011

The difference between concealment and blinding in clinical trials and why both are important. A reply to Garg and Mickenautsch, BMC Medical Research Methodology (2022) 22:17

por Lyden, Patrick, Broderick, Joseph, Grotta, James, Kwiatkowski, Thomas, Levine, Steven, Frankel, Michael, Haley, E. Clarke, Tilley, Barbara
Publicado 2023